Fosfomycin disodium salt, Antibiotic for Culture Media Use Only

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: Fosfomycin disodium salt, Antibiotic for Culture Media Use Only
• 英文别名: disodium;[(2R,3S)-3-methyloxiran-2-yl]-dioxido-oxo-λ5-phosphane
• 化学式: C3H5Na2O4P
• 分子量: 182.02
• InChiKey: QZIQJIKUVJMTDG-JSTPYPERSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -7.35
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  75.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Fosfomycin disodium salt, Antibiotic for Culture Media Use Only 生成 磷霉素
  参考文献：
  名称：

  BERTELLI, A.

  摘要：

  DOI：
• 作为产物：
  描述：

  (1-溴-2-羟丙基)膦酸 以63%的产率得到
  参考文献：
  名称：

  GIORDANO, CLAUDIO;CASTALDI, GRAZIANO, J. ORG. CHEM., 54,(1989) N, C. 1470-1473

  摘要：

  DOI：

文献信息

• INHALED FOSFOMYCIN/TOBRAMYCIN FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  申请人：Bhatt Elizabeth Peters

  公开号：US20110124589A1

  公开（公告）日：2011-05-26

  The present invention provides the use of an aerosol formulation comprising fosfomycin and tobramycin in the treatment of patients with chronic obstructive pulmonary disease (COPD) who are experiencing or are at risk of experiencing acute exacerbations of COPD. Formulations for such use and methods of treating humans with COPD are also provided.

  本发明提供了使用包含磷霉素和托布霉素的气雾剂制剂治疗患有慢性阻塞性肺疾病（COPD）且正在经历或有经历急性加重COPD风险的患者。还提供了用于此类用途的制剂和治疗COPD的方法。
• Aerosolized Fosfomycin/Aminoglycoside Combination for the Treatment of Bacterial Respiratory Infections
  申请人：Baker William

  公开号：US20130071442A1

  公开（公告）日：2013-03-21

  A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5μ, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.

  描述了一种通过气溶胶递送的福司莫汀加托布拉霉素联合配方。浓缩的福司莫汀加托布拉霉素联合配方含有足够的福司莫汀和托布拉霉素以抑制敏感的细菌。福司莫汀和托布拉霉素分别在双安瓿中配制，使得在重组后的pH值在4.5至8.0之间，或者以干粉的形式。通过喷射或超声波雾化器（或等效物）或干粉吸入器产生的质量介于1至5μ的质量平均直径为主要的气溶胶递送配方的方法用于治疗呼吸道感染。
• Aminoglycoside and Fosfomycin Combination for Treatment of Ventilator Associated Pneumonia (VAP) and Ventilator Associated Tracheal (VAT) Bronchitis
  申请人：Cardeas Pharma Inc.

  公开号：US20130303476A1

  公开（公告）日：2013-11-14

  The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

  本发明涉及抗生素组合物、基于呼吸机的系统和与呼吸机相关的肺炎（VAP）和气管插管相关的支气管炎（VAT）的方法。通过呼吸机内的行内雾化器给予福司莫司和氨基糖苷类药物，最好是阿米卡星的抗生素组合物。湿度条件创造了改进的气溶胶雾来治疗VAP和VAT。
• FORMULATIONS OF AMINOGLYCOSIDE AND FOSFOMYCIN COMBINATIONS AND METHODS AND SYSTEMS FOR TREATMENT OF VENTILATOR ASSOCIATED PNEUMONIA (VAP) AND VENTILATOR ASSOCIATED TRACHEAL (VAT) BRONCHITIS
  申请人：Cardeas Pharma Corporation

  公开号：US20150057242A1

  公开（公告）日：2015-02-26

  The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

  本发明涉及抗生素组合物、基于呼吸机的系统和与呼吸机相关的肺炎（VAP）和气管支气管炎（VAT）的治疗方法。将福司莫司和氨基糖苷类药物（优选为阿米卡星）的抗生素组合物通过呼吸机内联雾化器在呼吸机气道内给予。湿度条件创造了改进的气雾剂，以治疗VAP和VAT。
• Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
  申请人：Baker William

  公开号：US08980226B2

  公开（公告）日：2015-03-17

  A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5μ, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.

  描述了一种通过气溶胶递送的福司他霉素和庆大霉素联合配方。浓缩的福司他霉素和庆大霉素联合配方含有足够的福司他霉素和庆大霉素，能够抑制易感菌。福司他霉素和庆大霉素分别在双重安瓿中制备，使其重新溶解时的pH值在4.5至8.0之间，或者以干粉形式制备。通过气溶胶递送的配方用于治疗呼吸道感染，其质量中位数气动直径主要在1至5μ之间，由喷射或超声雾化器（或等效物）或干粉吸入器产生。